Scotiabank Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...
GEN - Genetic Engineering and Biotechnology News6h
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Notable healthcare headlines for the week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in focus
Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.
Wall Street Week Ahead
Stay updated with Wall Street's weekly highlights: key inflation data, CoreWeave IPO, and earnings reports. Insights on ...
5 Best CEFs This Month For Yields Up To 14%
For income investors, closed-end funds remain an attractive investment class. Check out this month's five CEFs with solid ...
Reuters23h
U.S. Markets
Nasdaq snaps four-week decline on tariff hopes March 21, 2025 U.S. Marketscategory Wall St Week Ahead Dow Transports index slump poses trouble spot as investors seek stocks stability 12:59 PM UTC ...